
Alnodesertib granted fast track designation by the FDA
The ATR inhibitor alnodesertib has been granted fast track designation by the US Food and Drug Administration (FDA), biopharmaceutical company Artios Pharma Limited has announced. Alnodesertib is a treatment for adult patients with ATM negative metastatic colorectal cancer (mCRC) in the third-line setting, in combination with a… Read More













